Why Bambusa Therapeutics’ BBT001 data are drawing attention in atopic dermatitis beyond a routine Phase 1 update
Bambusa Therapeutics’ BBT001 showed strong Phase 1 activity in atopic dermatitis. Read what it could change and what risks remain.
Pharma & Biotech
Pharma & Biotech
Connect Biopharma advances rademikibart data as global competition grows in eczema biologics
Rademikibart Phase 3 eczema data will debut at AAD 2026. Discover what the trial could mean for IL-4 receptor biologics and global dermatology drug competition.